Comparison of male prisoners in New South Wales and Queensland with and without penile implants.

#<p>None of the prisoners with penile inserts identified as gay or homosexual although one prisoner reported ‘other’ sexual identity.</p>*<p>Additional wording in the survey: [Interviewer guide indicated that such conditions as depression, schizophrenia, manic depressive, anxiety, personality disorder, alcohol dependence, drug dependence and ADD/ADHD should be included].</p>∧<p>Yes to any of the following: chlamydia, genital herpes, syphilis, gonorrhoea, non-specific urethritis (NSU), genital warts (including anal warts), trichomoniasis.</p

Additional file 1: Table S1. of Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data

Characteristics of the HIV-positive and HIV-negative HCV testing rate populations at the time of their first clinic visit. Values are presented as n (% of patients) unless otherwise indicated. *2073 individuals HIV seroconverted during follow up and contributed person years to both HIV-positive and HIV-negative study populations; HIV, human immunodeficiency virus; HCV, hepatitis C virus; IQR, interquartile range; MSM, men who have sex with men. Table S2. Characteristics of the HIV-positive and HIV-negative HCV re-testing rate populations at the time of their first documented HCV test. Values are presented as n (% of patients) unless otherwise indicated. *316 individuals HIV seroconverted during follow up and contributed person years to both HIV-positive and HIV-negative study populations; HIV, human immunodeficiency virus; HCV, hepatitis C virus; IQR, interquartile range; MSM, men who have sex with men. Table S3. Characteristics of the HCV incidence population at the time of their first negative HCV test. Values are presented as n (% of patients) unless otherwise indicated. HCV, hepatitis C virus; IQR, interquartile range; MSM, men who have sex with men; HIV, human immunodeficiency virus; ART, antiretroviral therapy. (DOCX 34 kb

Transmission mechanism for treatment-sensitive and treatment-resistant gonorrhoea as implemented in the model.

<p>Xs, Xr denote the infection status of person X: Xs = S if X is susceptible to treatment-sensitive gonorrhoea; Xs = I if X is infected with treatment-sensitive gonorrhoea. Similarly, Xr = S or Xr = I if X is susceptible or infected with treatment-resistant gonorrhoea, respectively. The diagram represents transmission from person X to person Y through unprotected sex act (transmission from Y to X is omitted in this diagram). The parameter <i>β</i> is the transmission probability per unprotected sex act. The parameters <i>A</i>_{<b><i>s</i></b>} and <i>A</i>_{<b><i>r</i></b>} are scalar adjustment to the transmission probability for treatment-sensitive and treatment-resistant gonorrhoea, respectively, and their value will be based on the infection status of person X and person Y as defined in the figure. <i>A</i>_{<b><i>s</i></b>} and <i>A</i>_{<b><i>r</i></b>} are equal to zero for all combinations not listed.</p

Scalar adjustment of transmission probability.

<p>Scalar adjustment of transmission probability as derived through the calibration process for the result shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133202#pone.0133202.g002" target="_blank">Fig 2</a>. Explanation of these parameters is given in the Methods and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133202#pone.0133202.g001" target="_blank">Fig 1</a>.</p

Impact of molecular test on AMR surveillance over 1000 simulation runs.

<p>IQR = interquartile range. The upper pane represents the situation where a molecular test is not available and AMR can only be detected from culture. The bottom panel represents the situation where AMR can be detected either by culture or molecular test.</p><p>*Based on the percentage of isolates available for culture in Western Australia [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133202#pone.0133202.ref009" target="_blank">9</a>]</p><p>**Based on the percentage of isolates available for culture in Northern Territory [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133202#pone.0133202.ref006" target="_blank">6</a>]</p><p>***Based on the percentage of isolates available for culture in Far North Queensland [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133202#pone.0133202.ref008" target="_blank">8</a>]</p><p>Impact of molecular test on AMR surveillance over 1000 simulation runs.</p

Factors associated with hospitalisation for PID.

<p>*based on SEIFA score (see methods),</p>+<p>based on ARIA score (see methods), individuals with unknown SEIFA or ARIA score were excluded from the multivariate analysis due to the high level of correlation.</p

Characteristics of women aged 15–45 at the time of chlamydia or gonorrhoea diagnosis, New South Wales 2000–2008.

<p>*based on SEIFA score (see methods),</p>+<p>based on ARIA score (see methods), IQR: Interquartile range.</p

Standardised* incidence ratio (SIR) for hospitalisation for pelvic inflammatory disease (PID) in women in New South Wales (NSW) aged 15–30. *standardised for age and year of follow-up.

<p>Standardised* incidence ratio (SIR) for hospitalisation for pelvic inflammatory disease (PID) in women in New South Wales (NSW) aged 15–30. *standardised for age and year of follow-up.</p

Distribution of time between chlamydia or gonorrhoea diagnosis and admission to hospital for pelvic inflammatory disease (PID).

<p>Distribution of time between chlamydia or gonorrhoea diagnosis and admission to hospital for pelvic inflammatory disease (PID).</p

POC test sensitivity among reference Treponemal immunoassay reactive specimens, by RPR reactivity and titre.

<p>Sensitivity of POC test result compared to reference treponemal immunoassays (IA); RPR = reactive plasma reagin; R = reactive; NR = non-reactive</p><p>Differences between estimates were considered to be statistically significant where 95% CI were not overlapping.</p